Is Crop Life Scienc overvalued or undervalued?

As of 17 October 2025, the valuation grade for Crop Life Science has moved from fair to expensive, indicating that the company is currently overvalued. The key ratios reflect this assessment, with a PE ratio of 14.50, an EV to EBITDA of 8.38, and a PEG ratio of 1.51. Compared to peers, Crop Life Science's valuation appears less attractive, especially when contrasted with UPL, which has a PE ratio of 37.91 and an EV to EBITDA of 9.14, and BASF India, boasting a PE ratio of 47.93 and an EV to EBITDA of 28.64.
Given these metrics and the overall market context, Crop Life Science is deemed overvalued. Additionally, while the company has outperformed the Sensex on a year-to-date basis with a return of 11.67% compared to the Sensex's 8.73%, this does not sufficiently justify its current valuation relative to its peers in the pesticides and agrochemicals industry.